Indirectly, alterations of intestinal permeability (IP) have also been detected in relapsing-remitting MS (RR-MS) patients (15), with zonulin being recognized as a peripheral marker of IP and blood–brain barrier (BBB) in MS (16). Here, HP is linked to myeloid sarcoma.